Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning

Robbins, Richard J.; Wan, Qiang; Grewal, Ravinder K.; Reibke, Roland; Gönen, Mithat; Strauss, H. William; Tuttle, R. Michael; Drucker, William D.; Larson, Steven M.

doi:10.1210/jc.2005-1534

Cited by 534 publications

(327 citation statements)

References 24 publications

Supporting

Mentioning

290

Contrasting

Unclassified

Order By: Relevance

“…In Figure 5, we show usage of the vortex map to identify errors when deformable registration is used in treatment response assessment to compare pre‐ and post‐treatment positron emission (PET) datasets 40 , 41 . In this approach, the baseline PET/CT scan is acquired up to a week before the start of the chemotherapeutic or radiotherapeutic treatment.…”

Section: Resultsmentioning

confidence: 99%

A measure to evaluate deformable registration fields in clinical settings

Schreibmann

Pantalone

Waller

et al. 2012

J Applied Clin Med Phys

View full text Add to dashboard Cite

Deformable registration has migrated from a research topic to a widely used clinical tool that can improve radiotherapeutic treatment accuracy by tracking anatomical changes. Although various mathematical formulations have been reported in the literature and implemented in commercial software, we lack a straightforward method to verify a given solution in routine clinical use. We propose a metric using concepts derived from vector analysis that complements the standard evaluation tools to identify unrealistic wrappings in a displacement field. At the heart of the proposed procedure is identification of vortexes in the displacement field that do not correspond to underlying anatomical changes. Vortexes are detected and their intensity quantified using the CURL operator and presented as a vortex map overlaid on the original anatomy for rapid identification of problematic regions. We show application of the proposed metric on clinical scenarios of adaptive radiotherapy and treatment response assessment, where the CURL operator quantitatively detected errors in the displacement field and identified problematic regions that were invisible to classical voxel‐based evaluation methods. Unrealistic warping not visible to standard voxel‐based solution assessment can produce erroneous results when the deformable solution is applied on a secondary dataset, such as dose matrix in adaptive therapy or PET data for treatment response assessment. The proposed metric for evaluating deformable registration provides increased usability and accuracy of detecting unrealistic deformable registration solutions when compared to standard intensity‐based approaches. It is computationally efficient and provides a valuable platform for the clinical acceptance of image‐guided radiotherapy.PACS numbers: 87.57.nj; 87.55.Qr; 87.57.cp

show abstract

Section: Resultsmentioning

confidence: 99%

A measure to evaluate deformable registration fields in clinical settings

Schreibmann

Pantalone

Waller

et al. 2012

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

“…In these cases, poorly differentiated follicular cells might lose the ability to concentrate RAI, synthesize sTg, and progressively enhance glucose metabolism due to high cell activity and metabolic demand. In this way, 18 F-FDG PET/CT has become a powerful tool to improve staging and tumor aggressiveness and investigate undifferentiated lesions that do not take up radioiodine, denoting important diagnostic and prognostic implications (18)(19)(20). The classical indication to perform 18 F-FDG PET/CT in thyroid cancer patients is positive sTg measurements with negative WBS uptake (6).…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

Yang

Maciel

Nakabashi

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: To evaluate the clinical utility of 18 F-FDG PET/CT in patients with high-risk DTC. Subjects and methods: Single-center retrospective study with 74 patients with high-risk differentiated thyroid cancer (DTC), classified in 4 groups. Group 1: patients with positive sTg or TgAb, subdivided in Group 1A: negative RxWBS and no foci of metastases identified at conventional image (n = 9); Group 1B: RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level (n = 13); Group 2: patients with histological findings of aggressive DTC variants (n = 21) and Group 3: patients with positive RxWBS (n = 31). Results: 18 F-FDG PET/CT identified undifferentiated lesions and helped restage the disease in groups 1B and 2. The scan helped guide clinical judgment in 9/13 (69%) patients of group 1B, 10/21 (48%) patients of group 2 and 2/31 (6%) patients of group 3. There was no clinical benefit associated with group 1A. 18 F-FDG PET/CT was associated with progressive disease. Conclusion: 18 F-FDG PET/CT is a useful tool in the follow-up of patients with high-risk DTC, mainly in the group of RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level and in those with aggressive DTC variants. Additionally, this study showed that 18 F-FDG PET/CT was associated with progression and helped display undifferentiated lesions guiding clinical assessments regarding surgeries or expectant treatments. Arch Endocrinol Metab. 2017;61(5):416-25.

show abstract

“…51 In addition, the correlation between FDG uptake and tumor grading is fairly weak for the majority of tumors; only gliomas, sarcomas, and thyroid cancers demonstrate strong correlations. 15,52,53 To make matters more complicated, some benign tumors, such as giant cell tumors, juvenile pilocytic astrocytomas, and Warthin tumors, frequently demonstrate intense FDG uptake. [54][55][56] Thus, although FDG uptake is modulated by several factors that often serve as poor prognostic markers, such as hypoxia, increased cellular proliferation, and the activation of a variety of oncogenes, the multifactorial etiology of increased FDG uptake limits its ability to assess for parameters other than glucose metabolism and may explain the variable success of FDG as a prognostic marker.…”

Section: Fdg-pet For Prognosismentioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

191

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning

Cited by 534 publications

References 24 publications

A measure to evaluate deformable registration fields in clinical settings

A measure to evaluate deformable registration fields in clinical settings

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

PET/CT imaging in cancer: Current applications and future directions

Contact Info

Product

Resources

About